What this study is
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.
Study details
- Sponsor
- University of Colorado, Denver
- Conditions
- Rheumatoid Arthritis · Interstitial Lung Disease
- Enrolling
- 750 people
- Starts
- 2017-06-22
- Est. completion
- 2027-06
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 45 Years – 90 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- ≥ 45years old
- Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria
You can't join if
- Inability to give informed consent
- Pregnant women
- History of interstitial lung disease
- Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
- Subjects over the age of 90 years old or less than 45 years old
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States
- Haylie A Lengel · Contact970-376-8303haylie.lengel@cuanschutz.edu
- Elizabeth O'Brien · Contact303-875-1844elizabeth.a.obrien@cuanschutz.edu
- Joce Lee, MD · Principal investigator
- Kristen Demoruelle, MD · Sub-investigator
- Jason Kolfenbach, MD · Sub-investigator
- Duane Pearson, MD · Sub-investigator
- Kevin Deane, MD · Sub-investigator
Recruiting
Study team
Sponsor
University of Colorado, Denver
Study ID 16-1097
Principal investigator
Joyce S Lee, MD
University of Colorado, Denver
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.